Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.
1 |
Ala-Kokko T et al. |
Vitamin D deficiency at admission is not associated with 90-day mortality in patients with severe sepsis or septic shock: Observational FINNAKI cohort study.
|
2 |
Efendijev I et al. |
Increased need for interventions predicts mortality in the critically ill.
|
3 |
Jalkanen V et al. |
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Are Elevated in Severe Pre-Eclampsia.
|
4 |
Jalkanen V et al. |
Sähkötupakkanesteen itsetuhoinen käyttö.
|
5 |
Karhe L et al. |
Development and Validation of the Caring Loneliness Scale.
|
6 |
Kiiski H et al. |
Increased plasma UCH-L1 after aneurysmal subarachnoid hemorrhage is associated with unfavorable neurological outcome.
|
7 |
Kuitunen A, Armstrong E. |
Vuotokomplikaatioiden hoito antikoagulaation aikana.
|
8 |
Laurikkala J et al. |
Mean arterial pressure and vasopressor load after out-of-hospital cardiac arrest: Associations with one-year neurologic outcome.
|
9 |
Lipcsey M et al. |
Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial.
|
10 |
Långsjö J et al. |
Critical neural targets for (the level of) human consciousness: Arousal arrest and unconsciousness after sumatriptan administration.
|
11 |
Mildh H et al. |
Three-year mortality in 30-day survivors of critical care with acute kidney injury: data from the prospective observational FINNAKI study.
|
12 |
Niemi-Murola L et al., toim. |
ANESTESIOLOGIAN JA TEHOHOIDON PERUSTEET, 3 p.
|
13 |
Palomäki A et al. |
Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital.
|
14 |
Pettilä V et al. |
Targeted tissue perfusion versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): study protocol and statistical analysis plan for a randomized controlled trial.
|
15 |
Raj R et al. |
Traumatic brain injury patient volume and mortality in neurosurgical intensive care units: a Finnish nationwide study.
|
16 |
Ristagno G et al. |
Elevated plasma heparin-binding protein is associated with early death after resuscitation from cardiac arrest .
|
17 |
Rygård SL et al. |
Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial.
|
18 |
Røsjø H et al. |
Prognostic Value of Secretoneurin in Critically Ill Patients With Infections.
|
19 |
Suomalainen P et al. |
Traumakäsikirja, Vaikeasti vammautuneen potilaan hoito Taysissa 2016.
|
20 |
Tirkkonen J et al. |
Aetiology of in-hospital cardiac arrest on general wards.
|
21 |
Tirkkonen J et al. |
Ethically justified treatment limitations in emergency situations.
|
22 |
Ukkonen M et al. |
Severe Sepsis in Elderly Patients Undergoing Gastrointestinal Surgery-a Prospective Multicenter Follow-up Study of Finnish Intensive Care Units.
|
23 |
Vaara ST et al. |
Urinary Biomarkers Indicative of Apoptosis and Acute Kidney Injury in the Critically Ill.
|
24 |
Vaara ST et al. |
Association of oliguria with the development of acute kidney injury in the critically ill.
|
25 |
Vahtera A. |
Tehohoito.
|
26 |
Vahtera A, Junttila E. |
Verenkierron arviointi ja seuranta (C=circulation).
|
27 |
Vahtera A, Junttila E. |
Verenkierron tehostettu valvonta.
|
28 |
Vahtera A, Junttila E. |
Akuutti verenkiertovajaus.
|
29 |
Vahtera A, Junttila E. |
Kudosten hapenpuute ja metabolinen asidoosi.
|
30 |
Vahtera A, Junttila E. |
Verenkiertovajauksen etiologia ja luokittelu.
|
31 |
Vahtera A, Junttila E. |
Verenkiertovajauksen hoito.
|
32 |
Vahtera A, Kuitunen A. |
Tehohoitopotilaan laskimotukosten ehkäisy.
|
33 |
Vahtera A et al. |
Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
|
34 |
Yang R et al. |
Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries.
|